Tagged with EY

R&D With the USD 62 billion deal from Japan’s Takeda Pharmaceutical to buy Irish firm Shire finally agreed after months of wrangling, we asked PharmaBoardroom’s readers whether this deal would herald a flurry of mergers and acquisitions (M&As) within the pharma world. “Biotech and pharma M&A activity dropped to its lowest…

Canada Dwight Gorham, president and CEO of Pillar5 Pharma, discusses the unique positioning of the CDMO in the multi-dose preservative free sterile ophthalmics space and stresses the importance of anticipating market trends in order to fuel expansion. Finally, he gives an insight into the importance of honing new skills and how…

Poland Krzysztof Kołodziejski, country manager of Santen Poland, discusses the strategy he put in place to modernize the business culture of the affiliate and how this has led to great success. Furthermore, he highlights the challenges being faced by innovative eyecare companies in Poland and the entire healthcare sector, as well…

Poland Stefan Jaworski-Martycz, country manager Poland and CEE Cluster Lead of Théa, a leading French ophthalmology company, discusses the intricacies of the Polish ophthalmology environment and the key steps for the Polish government to better value eyecare innovation. Additionally, he highlights the key growth drivers for the affiliate and the close…

Canada Mark Smithyes, president of Labtician Théa, highlights the company’s ambition to become the leader and preferred partner to optometrists and ophthalmologists in Canada by launching products from Laboratoires Théa’s innovative portfolio and building on Labtician Ophthalmics’ excellent reputation. Mark, what were the decisive pinpoints behind the joint venture between Labtician…

India Nikhil Masurkar, executive director of Entod Pharmaceuticals, talks about the company’s ambition to invest in stem cell research and become market leaders in the field of ophthalmology in ten years’ time by adding more cost-effective and highly effective dosage forms to their strong product portfolio. Can you briefly introduce your…

Brazil Luciano Marques, president of Alcon Brazil, provides insights into recent investments and innovative initiatives aimed at strengthening Alcon’s relationships with its partners and customers in Brazil, and also documents the heightening of the affiliate’s market access and medical affairs capacities and explains how these aspects have contributed to drive the…

Poland Jakub Szulc, director of life sciences at EY Poland, discusses the exciting opportunities that exist within the healthcare sector in the flourishing Polish economy and the overriding need to increase healthcare spending as the nation prepares for demographic changes in the future. Furthermore, he highlights the innovative services EY provides…

Tunisia Mohamed Khalil Tamim, Alcon’s head of regulatory affairs Africa manages the regulatory affairs of 47 countries in Alcon’s African cluster. He explains the necessity of creating and harmonizing medical device-specific regulatory frameworks in Africa for the benefit of patients, and documents Alcon’s strategy to navigate a price-sensitive market despite its…

India Sanjay Bhutani, managing director of Bausch & Lomb India and SAARC operations, gives his insights into the thriving visual care industry which has allowed the company to launch 31 intraocular lenses (IOLs) in the last three years and the Good and Services Tax (GST) which presents somewhat of a barrier…

Austria Günther Aschenbrenner, managing director of Théa Austria, a specialist French ophthalmology company, discusses the development of the company’s Austrian office since 2011 and how a strong portfolio acquired by Théa from Alcon has assisted them in growing rapidly. Furthermore, he provides an insight into the importance of long-term strategic thinking,…

Austria Austria has long been merely a cog in the wheel of global R&D, lying in the shadows of neighboring research giants, Germany and Switzerland. Now, however, this perception is changing as Austria capitalizes on its ideal central European location and impressively educated workforce. “From a biotech perspective, [Austria] has a…